Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

CETP antigenic peptide and fusion protein and their composition and applications

A fusion protein and antigenic peptide technology, applied in the field of antigenic peptides, can solve the problems of immunogenicity and insufficient efficiency

Active Publication Date: 2016-08-17
TAIPEI MEDICAL UNIV
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although a large number of antigens have been developed, their immunogenicity and efficiency are still not enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CETP antigenic peptide and fusion protein and their composition and applications
  • CETP antigenic peptide and fusion protein and their composition and applications
  • CETP antigenic peptide and fusion protein and their composition and applications

Examples

Experimental program
Comparison scheme
Effect test

example

[0109] Materials and Method

[0110] A DNA fragment of 6 repeated sequences encoding the human CETP epitope was constructed, and then it was fused with rabbit Fc and the fusion protein was expressed in E. coli BL21 (DE3).

[0111] As previously described (Hsu et al. 2000, Cancer Res. 60:3701-3705), the peptide PEHLLVDFLQSL encoding the human CETP epitope was generated by template repeat polymerase chain reaction (TR-PCR) (Gaofu et al. 2004, Vaccine 22: 3187-3194) DNA fragments of 6 repeating sequences ( figure 1 ). The adapter primers (Table 1) were then used to subject the TR-PCR product to adapter PCR to form restriction sites at the 5'end and 3'end to facilitate further subcloning. The 200-300bp linker PCR product ( figure 1 B) Eluted and cloned into T-Easy vector (Promega). The clones containing 6 copies of the CETP epitope were identified by sequencing and subcloning at the 3'end of the region encoding the Fc domain of rabbit IgG into a modified plasmid pET21b vector (Novage...

example 1

[0135] Example 1 Production of Fc-CETP6 vaccine

[0136] Generate DNA encoding 6 repeats of CETP epitope and induce and express the fusion protein in E. coli strain BL21 (DE3), such as figure 1 Shown in. The fusion protein Fc-CETP6 was purified by affinity chromatography on a histidine (His) binding column. The purity of the Fc-CETP6 fusion protein was checked by Coomassie Blue staining and Western blotting, and the purity reached 95%. The Fc-CETP purified by histidine binding 6 Purity: Lanes 1 to 3 show the staining results of Coomassie Blue for flow-through, washing and elutes, respectively, while Lane 4 shows that the eluate uses anti-rabbit IgG (Fc) Western blot analysis ( figure 1 C).

example 2

[0137] Example 2. In rabbits fed with HFC feed, Fc-CETP 6 The vaccine raises antibodies against CETP and reduces CETP activity

[0138] In order to confirm that the anti-CETP antibody is produced and the antibody reacts with CETP in the circulation, plasma anti-CETP titer and plasma CETP activity are measured. figure 2 A shows that in Fc-CETP 6 Anti-CETP antibodies were detected in the group from week 12 and the titer increased until the end of the study at week 24. figure 2 B shows that in the two groups fed with HFC feed, plasma CETP activity increased in a time-dependent manner, but in Fc-CETP 6 In the group, the plasma CETP activity was significantly lower. These results show that the injection of Fc-CETP 6 The production of antibodies against CETP is induced, which then reduces CETP activity.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure provides an antigenic peptide targeting the extracellular, but not the intracellular, form of CETP to reduce the level of LDL (including oxLDL and other derivatives of LDL) and increase the level of HDL. Accordingly, the disclosure provides a CETP vaccine to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity to prevent or treat oxLDL or other LDL derivative-related diseases / symptoms.

Description

Technical field [0001] The present invention relates to an antigen peptide for selectively inhibiting plasma cholesteryl ester transfer protein (CETP), but not cell cholesteryl ester transfer protein, a fusion protein containing the antigen peptide, and a method for eliciting CETP antibodies to Methods to reduce LDL levels and increase HDL levels. Specifically, the antigen peptide is a B cell epitope derived from CETP. Background technique [0002] HDL continues to receive attention because its level is negatively correlated with the risk of cardiovascular disease. This negative correlation can be attributed to its different potential anti-atherosclerotic properties, such as reverse cholesterol transport, anti-inflammatory, anti-oxidant and anti-thrombotic effects. Clinical studies have shown that low HDL-C is also found in non-alcoholic steatohepatitis (NASH). NASH shares several characteristics with atherosclerosis, including lipid accumulation, inflammation, and macrophage ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08C07K19/00C07K16/00C07K16/18A61K38/10A61K39/395A61P25/28A61P9/00A61P9/10A61P15/00A61P1/16A61P13/12A61P11/06
CPCA61K38/00C07K2317/33A61K45/06A61K39/0005C07K16/18A61P1/16A61P11/06A61P13/12A61P15/00A61P25/28A61P3/06A61P9/00A61P9/10C07K14/47C07K2317/24C07K2317/21C07K2319/30
Inventor 黃昭莲
Owner TAIPEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com